Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Manuel Barreiro de Acosta

Profesor Asociado

Universidade de Santiago de Compostela

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Epidemiology

20%

Internal Medicine

50%

Inflammatory Bowel Disease

70%

Inflammatory Disease

40%

Targeted Therapy

30%

Coronavirus Disease

20%

Pharmacoepidemiology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles13

Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

Article Link

Year:

2025

Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients

Article Link

Year:

2025

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

Article Link

Year:

2024

Recent Advances and Potential Multi-Omics Approaches in the Early Phases of Inflammatory Bowel Disease

Article Link

Year:

2023

Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

Article Link

Year:

2023

Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

Article Link

Year:

2022

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

Article Link

Year:

2022

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

Article Link

Year:

2022

Management and long-term outcomes of Crohn’s disease complicated with enterocutaneous fistula: ECUFIT study from GETECCU

Article Link

Year:

2022

Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy

Article Link

Year:

2022

Latin American consensus on the quality indicators for comprehensive care clinics for patients with inflammatory bowel disease: PANCCO-GETECCU

Article Link

Year:

2022

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Article Link

Year:

2022

Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

Article Link

Year:

2022

Collaborators13

Jordi Guardiola

Bellvitge University Hospital

SPAIN

Javier Pérez Gisbert

Tenure Professor

Universidad Autónoma de Madrid

SPAIN

ALEJANDRO HERNANDEZ CAMBA

Profesor Colaborador

SPAIN

Jose Luis Cabriada

Head of Department

Osakidetza Servicio Vasco de Salud

SPAIN

NOEMI MANCEÑIDO MARCOS

Profesor colaborador del Grado de Medicina

Universidad Autónoma de Madrid

SPAIN

Luis Bujanda

University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)

SPAIN

MARIA ESTEVE

Head of the Department

SPAIN

Toledo Lobo M. Val

Profesora Contratada Doctora

Universidad de Alcalá

SPAIN

Angel Ponferrada

Profesor Asociado

Universidad Complutense de Madrid

SPAIN

Pilar Nos

Head

Hospital Universitari i Politècnic La Fe

SPAIN

Richard Pollok

Consultant and Professor of Gastroenterology and GI infection

St George’s, University of London

UNITED KINGDOM

Fernando Gomollón

SPAIN

María Chaparro

SPAIN

How do I reach out?

Meet Kite AI